GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RVL Pharmaceuticals PLC (FRA:O1P) » Definitions » Enterprise Value

RVL Pharmaceuticals (FRA:O1P) Enterprise Value : €38.48 Mil (As of Jun. 10, 2024)


View and export this data going back to 2018. Start your Free Trial

What is RVL Pharmaceuticals Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, RVL Pharmaceuticals's Enterprise Value is €38.48 Mil. RVL Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-54.70 Mil. Therefore, RVL Pharmaceuticals's EV-to-EBIT ratio for today is -0.70.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, RVL Pharmaceuticals's Enterprise Value is €38.48 Mil. RVL Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was €-54.33 Mil. Therefore, RVL Pharmaceuticals's EV-to-EBITDA ratio for today is -0.71.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, RVL Pharmaceuticals's Enterprise Value is €38.48 Mil. RVL Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was €35.25 Mil. Therefore, RVL Pharmaceuticals's EV-to-Revenue ratio for today is 1.09.


RVL Pharmaceuticals Enterprise Value Historical Data

The historical data trend for RVL Pharmaceuticals's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RVL Pharmaceuticals Enterprise Value Chart

RVL Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Enterprise Value
Get a 7-Day Free Trial 499.55 473.36 272.30 84.04 104.94

RVL Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 117.02 215.01 104.94 126.78 87.17

Competitive Comparison of RVL Pharmaceuticals's Enterprise Value

For the Biotechnology subindustry, RVL Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RVL Pharmaceuticals's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RVL Pharmaceuticals's Enterprise Value distribution charts can be found below:

* The bar in red indicates where RVL Pharmaceuticals's Enterprise Value falls into.



RVL Pharmaceuticals Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

RVL Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2022 is calculated as

RVL Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RVL Pharmaceuticals  (FRA:O1P) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

RVL Pharmaceuticals's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=38.480/-54.695
=-0.70

RVL Pharmaceuticals's current Enterprise Value is €38.48 Mil.
RVL Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-54.70 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

RVL Pharmaceuticals's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=38.480/-54.331
=-0.71

RVL Pharmaceuticals's current Enterprise Value is €38.48 Mil.
RVL Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-54.33 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

RVL Pharmaceuticals's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=38.480/35.251
=1.09

RVL Pharmaceuticals's current Enterprise Value is €38.48 Mil.
RVL Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €35.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RVL Pharmaceuticals Enterprise Value Related Terms

Thank you for viewing the detailed overview of RVL Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


RVL Pharmaceuticals (FRA:O1P) Business Description

Traded in Other Exchanges
Address
400 Crossing Boulevard, Bridgewater, NJ, USA, 08807
RVL Pharmaceuticals PLC is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Its revenues consist of product sales, royalty revenues and licensing revenue.

RVL Pharmaceuticals (FRA:O1P) Headlines

No Headlines